A long and lonely road to nowhere ahead for TIGIT?

This morning Genentech/Roche dropped a press release providing the dreaded ‘update on’ the much anticipated interim results from SKYSCRAPER–01 phase 3 trial.

When you see language such as this, you know before you open the release the outcome will more than likely be a negative one.

Unfortunately, 2022 has already been a long year of doom and gloom for oncology trial readouts and we’re still only in May.

In our latest in-depth review we discuss what can we learn from the latest findings and how might this result impact the broader TIGIT niche?

To read our latest discussion on oncology new product development plus commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by